Viridian Therapeutics, Inc./DE Net Income (Loss) Available to Common Stockholders, Diluted
Viridian Therapeutics, Inc./DE (VRDN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$25.69 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-05-13
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for the quarter ending 2022-03-31 was -$25.69M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$28.95M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$14.04M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$17.96M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for fiscal 2021 was -$79.41M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, diluted for fiscal 2020 was -$110.72M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$25.69M 10-Q · filed 2022-05-13 | -$54.64M derived: sum of 2 quarters · filed 2022-05-13 | -$68.68M derived: sum of 3 quarters · filed 2022-05-13 | -$86.65M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-12-31 | -$28.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$42.99M derived: sum of 2 quarters · filed 2022-03-11 | -$60.95M derived: sum of 3 quarters · filed 2022-03-11 | -$79.41M 10-K · filed 2022-03-11 |
| 2021-09-30 | -$14.04M 10-Q · filed 2021-11-05 | -$32.01M derived: sum of 2 quarters · filed 2021-11-05 | -$50.47M 10-Q · filed 2021-11-05 | -$141.21M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-06-30 | -$17.96M 10-Q · filed 2021-08-12 | -$36.42M 10-Q · filed 2021-08-12 | -$127.17M derived: sum of 3 quarters · filed 2022-05-13 | -$132.66M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-03-31 | -$18.46M 10-Q · filed 2022-05-13 | -$109.20M derived: sum of 2 quarters · filed 2022-05-13 | -$114.70M derived: sum of 3 quarters · filed 2022-05-13 | -$121.13M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$90.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$96.24M derived: sum of 2 quarters · filed 2022-03-11 | -$102.67M derived: sum of 3 quarters · filed 2022-03-11 | -$110.72M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$5.49M 10-Q · filed 2021-11-05 | -$11.93M derived: sum of 2 quarters · filed 2021-11-05 | -$19.97M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$6.43M 10-Q · filed 2021-08-12 | -$14.48M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |